Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis.

Literature DB >> 8609517

A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis.

M Lai¹, T Hodgson, M Gawne-Cain, S Webb, D MacManus, W I McDonald, A J Thompson, D H Miller.

Abstract

Long TR and gadolinium enhanced spin echo brain MRI was performed weekly for three months in three patients with relapsing-remitting or secondary progressive multiple sclerosis. During the study, 38 new enhancing lesions were seen; 11 showed enhancement for less than four weeks, and two enhanced on only one scan. All 16 new lesions seen on long TR scans showed initial enhancement. When only every fourth (monthly) scan was analysed, a total of 33 new enhancing lesions were seen. Subject to confirmation in a larger cohort, the results suggest: (a) that blood brain barrier leakage is an invariable event in new lesion development in relapsing-remitting and secondary progressive multiple sclerosis; (b) the small increase in sensitivity of weekly scanning does not justify its use in preference to monthly scanning when monitoring treatments.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1996 PMID： 8609517 PMCID： PMC1073863 DOI： 10.1136/jnnp.60.3.339

Source DB: PubMed Journal: J Neurol Neurosurg Psychiatry ISSN： 0022-3050 Impact factor: 10.154

17 in total

1. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.

Authors: F Barkhof; P Scheltens; S T Frequin; J J Nauta; M W Tas; J Valk; O R Hommes
Journal: AJR Am J Roentgenol Date: 1992-11 Impact factor: 3.959

2. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications.

Authors: A G Kermode; A J Thompson; P Tofts; D G MacManus; B E Kendall; D P Kingsley; I F Moseley; P Rudge; W I McDonald
Journal: Brain Date: 1990-10 Impact factor: 13.501

3. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration.

Authors: A J Thompson; D Miller; B Youl; D MacManus; S Moore; D Kingsley; B Kendall; A Feinstein; W I McDonald
Journal: Neurology Date: 1992-01 Impact factor: 9.910

4. New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors: C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal: Ann Neurol Date: 1983-03 Impact factor: 10.422

5. Gadopentetate dimeglumine enhancement of multiple sclerosis lesions on long TR spin-echo images at 0.6 T.

Authors: F Barkhof; J Valk; O R Hommes; P Scheltens; J J Nauta
Journal: AJNR Am J Neuroradiol Date: 1992 Jul-Aug Impact factor: 3.825

6. Multiple sclerosis: a serial study using MRI in relapsing patients.

Authors: C Isaac; D K Li; M Genton; C Jardine; E Grochowski; M Palmer; L F Kastrukoff; J Oger; D W Paty
Journal: Neurology Date: 1988-10 Impact factor: 9.910

7. Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis.

Authors: S Bastianello; C Pozzilli; S Bernardi; L Bozzao; L M Fantozzi; C Buttinelli; C Fieschi
Journal: Neurology Date: 1990-04 Impact factor: 9.910

8. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis.

Authors: M Filippi; A Campi; V Martinelli; B Colombo; T Yousry; N Canal; G Scotti; G Comi
Journal: J Neurol Neurosurg Psychiatry Date: 1995-11 Impact factor: 10.154

9. Gadolinium-pentetic acid magnetic resonance imaging in patients with relapsing remitting multiple sclerosis.

Authors: R Capra; N Marcianò; L A Vignolo; A Chiesa; R Gasparotti
Journal: Arch Neurol Date: 1992-07

10. Major differences in the dynamics of primary and secondary progressive multiple sclerosis.

Authors: A J Thompson; A G Kermode; D Wicks; D G MacManus; B E Kendall; D P Kingsley; W I McDonald
Journal: Ann Neurol Date: 1991-01 Impact factor: 10.422

8 in total

1. Dirty-appearing white matter in multiple sclerosis: volumetric MR imaging and magnetization transfer ratio histogram analysis.

Authors: Yulin Ge; Robert I Grossman; James S Babb; Juan He; Lois J Mannon
Journal: AJNR Am J Neuroradiol Date: 2003 Nov-Dec Impact factor: 3.825

A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis.

1. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.

2. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications.

3. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration.

4. New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

5. Gadopentetate dimeglumine enhancement of multiple sclerosis lesions on long TR spin-echo images at 0.6 T.

6. Multiple sclerosis: a serial study using MRI in relapsing patients.

7. Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis.

8. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis.

9. Gadolinium-pentetic acid magnetic resonance imaging in patients with relapsing remitting multiple sclerosis.

10. Major differences in the dynamics of primary and secondary progressive multiple sclerosis.

1. Dirty-appearing white matter in multiple sclerosis: volumetric MR imaging and magnetization transfer ratio histogram analysis.

Review 2. Imaging of multiple sclerosis: role in neurotherapeutics.

3. Multiple sclerosis: the evolving diagnostic criteria for multiple sclerosis.

4. New imaging techniques in the diagnosis of multiple sclerosis.

Review 5. Biomarkers and surrogate outcomes in neurodegenerative disease: lessons from multiple sclerosis.

Review 6. Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis.

Review 7. 'No evidence of disease activity' - is it an appropriate surrogate in multiple sclerosis?

8. Prognostic value of white matter lesion shrinking in early multiple sclerosis: An intuitive or naïve notion?